{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:43:15Z","timestamp":1790757795929,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important pathway responsible for antibody-mediated rejection (AMR). Imlifidase (IdeS) cleaves human IgG into F(ab\u2019)<jats:sub>2<\/jats:sub> and Fc fragments, potentially inhibiting ADCC. Here we examined the effect of IdeS on allo-antibody-mediated NK cell activation (Allo-CFC) and ADCC in vitro.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>For Allo-CFC, normal whole blood was incubated with third-party peripheral blood mononuclear cells (PBMCs) pretreated with anti-HLA antibody positive (HS) or negative (NC) sera to measure IFN\u03b3+ NK cell%. For ADCC, normal PBMCs were incubated with Farage B (FB) cells with HS or NC sera to measure 7-AAD+ lysed FB cell%. To assess the effect of IdeS on these assays, serum-treated PBMCs (Allo-CFC-1) and serum used for PBMC pretreatment (Allo-CFC-2) in Allo-CFC, and serum used for ADCC were preincubated with IdeS. Sera from IdeS-treated patients were also tested for Allo-CFC (Allo-CFC-3).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>IFN\u03b3+ NK cell% were significantly elevated in HS versus NC sera in Allo-CFC-1 (10 \u00b1 3% versus 2 \u00b1 1%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001), Allo-CFC-2 (20 \u00b1 10% versus 4 \u00b1 2%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01) and 7AAD+ FB cell% (11 \u00b1 3% versus 4 \u00b1 2%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02) in ADCC. These were significantly reduced by IdeS treatment. Patient sera with significantly reduced anti-HLA antibody levels at 1 day postimlifidase lost the capacity to activate NK cells in Allo-CFC-3, but those at 1\u20133 months postimlifidase regained the capacity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>IdeS inhibited NK cell activation and ADCC in vitro and in treated patients. These results and reported inhibition of complement activating anti-HLA antibodies by IdeS suggest its possible role in treatment of AMR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003023","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T15:08:44Z","timestamp":1571843324000},"page":"1574-1579","source":"Crossref","is-referenced-by-count":40,"title":["Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro"],"prefix":"10.1097","volume":"104","author":[{"given":"Shili","family":"Ge","sequence":"first","affiliation":[{"name":"Transplant Immunology Laboratory, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Chu","sequence":"additional","affiliation":[{"name":"Transplant Immunology Laboratory, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jua","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Louie","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Transplant Immunology Laboratory, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2015.02.004","article-title":"The perfect storm: HLA antibodies, complement, fc\u03b3rs, and endothelium in transplant rejection.","volume":"21","author":"Thomas","year":"2015","journal-title":"Trends Mol Med"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.humimm.2012.07.330","article-title":"Role of complement and NK cells in antibody mediated rejection.","volume":"73","author":"Akiyoshi","year":"2012","journal-title":"Hum Immunol"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/TP.0b013e3182802f88","article-title":"Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.","volume":"95","author":"Vo","year":"2013","journal-title":"Transplantation"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"6804678","DOI":"10.1155\/2017\/6804678","article-title":"Desensitization: overcoming the immunologic barriers to transplantation.","volume":"2017","author":"Sethi","year":"2017","journal-title":"J Immunol Res"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1097\/TXD.0000000000000821","article-title":"Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients.","volume":"4","author":"Jordan","year":"2018","journal-title":"Transplant Direct"},{"key":"R6-20231002","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13042","article-title":"Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.","volume":"21","author":"Kim","year":"2017","journal-title":"Pediatr Transplant"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/tri.12832","article-title":"Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.","volume":"29","author":"Kahwaji","year":"2016","journal-title":"Transpl Int"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.","volume":"21","author":"von Pawel-Rammingen","year":"2002","journal-title":"Embo J"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"17371","DOI":"10.1073\/pnas.0407965101","article-title":"Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG.","volume":"101","author":"Wenig","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"e0132011","DOI":"10.1371\/journal.pone.0132011","article-title":"Complete removal of extracellular igg antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS\u2014a novel therapeutic opportunity.","volume":"10","author":"Winstedt","year":"2015","journal-title":"Plos One"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","article-title":"Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.","volume":"83","author":"Tradtrantip","year":"2013","journal-title":"Mol Pharmacol"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation.","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/ajt.14733","article-title":"Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.","volume":"18","author":"Lorant","year":"2018","journal-title":"Am J Transplant"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0000000000002924","article-title":"IdeS (imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody.","volume":"268","author":"Lonze","year":"2018","journal-title":"Ann Surg"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.trim.2011.11.001","article-title":"Ifn\u03b3 production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens.","volume":"26","author":"Toyoda","year":"2012","journal-title":"Transpl Immunol"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trim.2009.11.004","article-title":"Intracellular IFNgamma production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization.","volume":"22","author":"Toyoda","year":"2010","journal-title":"Transpl Immunol"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.TP.0000438636.52085.50","article-title":"Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents.","volume":"97","author":"Shin","year":"2014","journal-title":"Transplantation"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1097\/TXD.0000000000000653","article-title":"Tocilizumab (anti-IL-6R) suppressed tnf\u03b1 production by human monocytes in an in vitro model of anti-HLA antibody-induced antibody-dependent cellular cytotoxicity.","volume":"3","author":"Shin","year":"2017","journal-title":"Transplant Direct"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0966-3274(94)90012-4","article-title":"Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin.","volume":"2","author":"Toyoda","year":"1994","journal-title":"Transpl Immunol"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/ajt.13580","article-title":"Liver transplantation in a patient with CD40 ligand deficiency and hyper-IgM syndrome: clinical and immunological assessments.","volume":"16","author":"Tseng","year":"2016","journal-title":"Am J Transplant"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1084\/jem.162.6.2089","article-title":"Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express fc receptors for igg (CD16\/leu-11 antigen).","volume":"162","author":"Lanier","year":"1985","journal-title":"J Exp Med"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"15540","DOI":"10.1021\/bi048284d","article-title":"Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for igg cleavage due to exosite binding.","volume":"43","author":"Vincents","year":"2004","journal-title":"Biochemistry"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molimm.2011.08.002","article-title":"The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity.","volume":"49","author":"Su","year":"2011","journal-title":"Mol Immunol"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/exd.13163","article-title":"In vivo enzymatic modulation of igg antibodies prevents immune complex-dependent skin injury.","volume":"26","author":"Mihai","year":"2017","journal-title":"Exp Dermatol"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/ndt\/gfq115","article-title":"Successful treatment of experimental glomerulonephritis with IdeS and endos, IgG-degrading streptococcal enzymes.","volume":"25","author":"Yang","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"5672523","DOI":"10.1155\/2017\/5672523","article-title":"Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients.","volume":"2017","author":"Toyoda","year":"2017","journal-title":"J Immunol Res"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/ejh.13170","article-title":"NKT cells\u2014new players in CAR cell immunotherapy?","volume":"101","author":"Kriegsmann","year":"2018","journal-title":"Eur J Haematol"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bmb\/ldv013","article-title":"Kidney transplantation in highly sensitized patients.","volume":"114","author":"Jordan","year":"2015","journal-title":"Br Med Bull"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:23:34Z","timestamp":1696224214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003023","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,21]]}}}